Research theme for competitive and other funds (7):
2020 - 2023 Investigation of new therapeutic target of renal cell carcinoma resistant to a tyrosine kinase inhibitor by elucidating the drug tolerance by cancer metabolomics
坂井孝成, 川崎芳英, 諸角謙人, 方山博路, 嶋田修一, 佐藤琢磨, 佐竹洋平, 川守田直樹, 山下慎一, 伊藤明宏. Selection of first-line therapy for advanced renal cell carcinoma at Tohoku University Hospital. 日本泌尿器科学会総会(Web). 2023. 110th
川守田直樹, 石塚雄一, 木村信吾, 田中峻希, 方山博路, 佐竹洋平, 佐藤琢磨, 嶋田修一, 川崎芳英, 山下慎一, et al. Patient-reported outcome of urinary function and bother from shortly after robot-assisted radical prostatectomy. 日本泌尿器科学会総会(Web). 2023. 110th
川崎芳英, 川守田直樹, 方山博路, 佐竹洋平, 佐藤琢磨, 嶋田修一, 山下慎一, 伊藤明宏. Laparoscopic radical nephrectomy for renal cell carcinoma with renal venous thrombus from the viewpoint of safety and certainty. 泌尿器外科. 2023. 36
勝又有記, 嶋田修一, 方山博路, 佐竹洋平, 佐藤琢磨, 川崎芳英, 川守田直樹, 山下慎一, 伊藤明宏. Predictive factors in patients with metastatic urothelial carcinoma treated with pembrolizumab: 36 month follow-up study in Japanese patients. 日本泌尿器科学会総会(Web). 2023. 110th